scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Core Insights - scPharmaceuticals reported a significant increase in net FUROSCIX revenue, reaching $16 million in Q2 2025, which is a 99% increase compared to Q2 2024 [1][3] - The company has expanded FUROSCIX into the chronic kidney disease market, which is seen as a critical step in enhancing diuretic therapy delivery [2] - The Autoinjector for FUROSCIX is on track for sNDA submission in Q3 2025, aiming to reduce treatment time from five hours to less than ten seconds [1][3] Financial Performance - Net FUROSCIX revenue for Q2 2025 was $16.0 million, compared to $8.1 million in Q2 2024, indicating approximately 99% annual growth [3][4] - Approximately 20,200 FUROSCIX doses were filled in Q2 2025, a 117% increase from about 9,300 doses in Q2 2024 [3] - The gross-to-net (GTN) discount increased to 27% in Q2 2025 from 23% in Q1 2025 [3] Expenses - Cost of product revenues for Q2 2025 was $5.0 million, up from $2.3 million in Q2 2024, driven by increased demand and manufacturing costs [4] - Research and development expenses rose to $4.1 million in Q2 2025 from $2.7 million in Q2 2024, primarily due to higher device and pharmaceutical development costs [5] - Selling, general, and administrative expenses increased to $21.2 million in Q2 2025 from $17.5 million in Q2 2024, mainly due to higher employee-related and commercial costs [6] Losses and Cash Position - The company reported a net loss of $18.0 million for Q2 2025, compared to a net loss of $17.1 million in Q2 2024 [7] - As of June 30, 2025, cash and cash equivalents stood at $40.8 million, down from $75.7 million at the end of 2024 [21]